Press Releases

CRANBURY, N.J., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus (Nasdaq: FOLD) will announce first quarter 2008 financial results after the regular close of markets on Tuesday, May 13, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. EDT. Interested participants ...  

CRANBURY, N.J., March 13, 2008 /PRNewswire via COMTEX News Network/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present positive results from an ex vivo response study and three Phase 1...  

CRANBURY, N.J., Feb 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at BIO CEO & Investor Conference 2008 in New York, NY on Monday, February 11, 2008 at 12:30 pm (Eastern Standard Time) at...  

CRANBURY, N.J., Jan 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally- active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the fourth quarter and full year of 2007. On a reported...  

CRANBURY, N.J., Jan 02, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), today announced that John F. Crowley, President and Chief Executive Officer, will present a corporate update at the 26th Annual JPMorgan Healthcare Conference in San Francisco, CA on Monday, January 7, 2008 at 11:30 am (Pacific St...  

CRANBURY, N.J., Nov 27, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that it will host an "R&D Day" meeting on December 19, 2007 from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. The presentation will include a summary of the results of the Phase 2 clinical trials performed...  

CRANBURY, N.J., Nov 08, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics, Inc. (Nasdaq: FOLD) announced today that it has entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a subsidiary of Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), to jointly develop Amicus' three lead pharmacological chap...  

CRANBURY, N.J., October 23, 2007 -- Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of a range of human genetic diseases, announced today positive results from two recently completed Phase 1 clinical studies of AT2220 (1-deoxynojirimycin HCl) f...  

CRANBURY, N.J., Sept 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced that John Crowley, President and Chief Executive Officer, will present a corporate update at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference in London, United Kingdom on Tuesday, September 18t...  

ADVISORY, May 31, 2007 (PrimeNewswire via COMTEX News Network) -- What: John F. Crowley, President and Chief Executive Officer of Amicus Therapeutics (FOLD), will preside over the closing bell to celebrate the Company's initial public offering on NASDAQ. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Stud...